Merit Medical Systems (NASDAQ:MMSI) Share Price Breaks Below 50 Day Moving Average – Time to Sell?

Merit Medical Systems, Inc. (NASDAQ:MMSI)’s share price crossed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $88.60 and traded as low as $84.00. Merit Medical Systems shares last traded at $86.24, with a volume of 1,804,091 shares trading hands.

More Merit Medical Systems News

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Strong Q3 earnings beat expectations. Merit reported third-quarter revenue of $416.2 million, up 8.4% year over year and ahead of the $410.6 million consensus estimate. Non-GAAP EPS was $1.12 versus expectations of $1.04, while GAAP EPS rose 51% to $0.70. Merit Medical Q3 2026 results
• Positive Sentiment: Profitability and cash generation improved. Organic constant-currency revenue increased 9%, GAAP operating margin expanded to 14.1% from 11.1%, and year-to-date operating cash flow reached $175.2 million, with $129.5 million in free cash flow.
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 earnings outlook following the strong quarter, supporting expectations for continued growth. Merit Medical raises 2026 guidance
• Positive Sentiment: Analysts raised targets. BTIG Research lifted its target from $105 to $110 and maintained a buy rating. Wells Fargo raised its target from $83 to $92, although it retained an equal-weight rating. Analysts raise Merit Medical price targets
• Positive Sentiment: Cardiac-therapy capabilities expanded. Merit acquired Solo Pace, adding temporary pacing technology designed for patients with aortic stenosis and strengthening its TAVR-related product portfolio. Merit Medical acquires Solo Pace
• Neutral Sentiment: Valuation remains a consideration. With the stock trading at roughly 36 times earnings and near its 52-week high, investors may be demanding continued execution, leaving limited room for disappointment.
• Negative Sentiment: Some caution remains among analysts. Wells Fargo’s equal-weight rating and the company’s narrowed sales outlook temper the bullish impact of the earnings beat and guidance increase.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Wells Fargo & Company upped their target price on Merit Medical Systems from $83.00 to $92.00 and gave the stock an “equal weight” rating in a report on Friday. Bank of America upped their price target on shares of Merit Medical Systems from $92.00 to $97.00 and gave the company a “neutral” rating in a research report on Thursday, August 13th. Barrington Research set a $114.00 price objective on Merit Medical Systems in a research note on Friday, July 31st. Zacks Research downgraded shares of Merit Medical Systems from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 19th. Finally, Robert W. Baird set a $98.00 price objective on shares of Merit Medical Systems in a research note on Friday, July 31st. Eight investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $105.55.

Merit Medical Systems Stock Down 7.7%

The business has a fifty day moving average price of $88.60 and a two-hundred day moving average price of $77.14. The company has a debt-to-equity ratio of 0.44, a current ratio of 4.20 and a quick ratio of 2.79. The firm has a market capitalization of $5.15 billion, a price-to-earnings ratio of 32.42, a price-to-earnings-growth ratio of 2.15 and a beta of 0.51.

Merit Medical Systems (NASDAQ:MMSI) last posted its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.04 by $0.08. The company had revenue of $416.24 million during the quarter, compared to analyst estimates of $410.56 million. Merit Medical Systems had a net margin of 9.94% and a return on equity of 14.37%. Merit Medical Systems’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period last year, the firm posted $0.92 EPS. On average, equities analysts expect that Merit Medical Systems, Inc. will post 3.84 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Boston Trust Walden Corp grew its position in shares of Merit Medical Systems by 12.4% in the third quarter. Boston Trust Walden Corp now owns 531,396 shares of the medical instruments supplier’s stock valued at $45,822,000 after purchasing an additional 58,540 shares in the last quarter. Chicago Partners Investment Group LLC purchased a new position in Merit Medical Systems during the third quarter worth approximately $213,000. Mountain Pacific Investment Advisers LLC lifted its position in Merit Medical Systems by 88.8% during the third quarter. Mountain Pacific Investment Advisers LLC now owns 38,048 shares of the medical instruments supplier’s stock worth $3,281,000 after buying an additional 17,899 shares in the last quarter. Salomon & Ludwin LLC boosted its stake in Merit Medical Systems by 140.8% during the third quarter. Salomon & Ludwin LLC now owns 537 shares of the medical instruments supplier’s stock worth $46,000 after buying an additional 314 shares during the last quarter. Finally, Vise Technologies Inc. grew its holdings in Merit Medical Systems by 15.5% in the 3rd quarter. Vise Technologies Inc. now owns 19,134 shares of the medical instruments supplier’s stock valued at $1,650,000 after buying an additional 2,567 shares in the last quarter. 99.66% of the stock is currently owned by hedge funds and other institutional investors.

About Merit Medical Systems

Merit Medical Systems, Inc is a medical device company that develops, manufactures and distributes disposable products used in interventional, diagnostic and therapeutic procedures. Its devices are designed for use by healthcare professionals in hospitals, outpatient facilities and other clinical settings.

The company’s product portfolio includes devices for vascular access, angiography, intervention, drainage, embolization, oncology and cardiac procedures. Merit also offers products used in peripheral intervention, spine procedures and other specialized areas of minimally invasive medicine, including kits, accessories and related procedural equipment.

Founded in 1987 and headquartered in South Jordan, Utah, Merit Medical serves healthcare providers through a global commercial and manufacturing network.